At a glance
Platelet-rich plasma (PRP) is being investigated as a possible treatment for female stress urinary incontinence (SUI), but the evidence is still developing. Small trials have reported mixed results, and current research does not establish PRP as a first-line treatment. Assessment, pelvic-floor management and other established care pathways remain important when deciding what treatment is appropriate.
Stress urinary incontinence can affect daily activity, exercise, work and sexual wellbeing. Because urinary leakage can have different causes, treatment should start with understanding the type of incontinence and the factors contributing to it rather than selecting a procedure based on symptoms alone.
What is stress urinary incontinence?
Stress urinary incontinence is involuntary urine leakage during activities that increase pressure inside the abdomen, such as coughing, sneezing, laughing, lifting, running or other exercise. It is different from urge incontinence, where leakage is associated with a sudden compelling need to pass urine, and from mixed incontinence, where both patterns occur.
Pregnancy and childbirth, pelvic-floor weakness or injury, ageing, menopause, chronic cough, constipation, higher body weight and other health factors may contribute. A clinical history and, where appropriate, examination or further investigation can help distinguish SUI from other bladder or pelvic-floor conditions.
What is platelet-rich plasma?
PRP is prepared from a person’s own blood. The blood is processed to produce plasma containing a higher concentration of platelets than whole blood. Researchers have investigated whether injecting autologous PRP around the urethral or anterior vaginal tissues might influence symptoms of SUI.
PRP preparation methods, injection sites, schedules and outcome measures vary between studies. That variation is one reason results cannot simply be combined into a single predictable treatment effect for an individual patient.
Established care
Pelvic-floor muscle training and other conservative strategies remain central parts of SUI management.
PRP research
Small randomized and observational studies have produced both positive and neutral findings.
Current interpretation
PRP remains an emerging area of research rather than an established first-line option.
Why is PRP being studied for SUI?
Researchers are interested in whether autologous platelet concentrates might influence tissue function around the urethra and pelvic support structures. This remains a research question. Proposed biological mechanisms should not be treated as proof that a clinical benefit will occur.
Earlier studies often used small participant numbers, different injection techniques and different treatment schedules. Some also combined PRP with other interventions, which makes it difficult to determine the independent contribution of PRP.
What does the current research show?
The evidence is mixed. A 2024 randomized sham-controlled trial involving 50 women reported greater improvement in several SUI measures after a two-injection PRP protocol than after sham treatment. Another randomized placebo-controlled study, also involving 50 participants, assessed a single PRP injection and found no statistically significant difference in its primary composite treatment-success outcome at six months compared with saline placebo.
A separate randomized trial comparing pelvic-floor muscle training alone with PRP plus pelvic-floor muscle training reported some improved leakage and symptom outcomes in the combined group, but the authors stated that larger phase III trials were required.
A 2026 systematic review and meta-analysis pooled eight studies involving 257 women and found short-term improvements across several symptom and urodynamic measures. The authors nevertheless concluded that larger, standardised randomized trials with longer follow-up are needed to determine durability and define PRP’s role relative to established treatments.
What this means: early signals of benefit in some studies do not establish that PRP is effective for every patient, identify an optimal protocol, or show how it compares over the long term with established SUI treatments. The evidence should be described as evolving, not settled.
What are the main limitations in the evidence?
Current studies are relatively small and use different methods. Important differences include patient selection, PRP preparation, injection location, number and timing of treatments, comparator groups and the questionnaires or objective tests used to measure outcomes.
Follow-up is also generally short. Small studies are not well suited to detecting uncommon complications or answering questions about long-term durability. Although published trials have generally reported few serious short-term adverse events, the size and duration of the evidence base are not sufficient to define uncommon or long-term risks with confidence.
These limitations are important when discussing any emerging intervention. A statistically significant change in a study outcome is not the same as demonstrating a reliable, durable or clinically appropriate treatment for every person with SUI.
What established treatment pathways are available for SUI?
Australian consumer guidance describes pelvic-floor muscle training as an important management option for stress incontinence. A pelvic health physiotherapist or continence professional can assess pelvic-floor strength, coordination and technique and tailor a program to the individual.
Other management may include addressing constipation, chronic cough, smoking, weight or bladder habits where relevant. Some women may benefit from continence devices or specialist review. When conservative measures are insufficient and symptoms remain significant, a gynaecologist, urogynaecologist or urologist can discuss further procedural or surgical options according to the diagnosis, severity of symptoms, medical history and patient preferences.
When is further assessment useful?
Further assessment is appropriate when leakage is persistent, worsening, difficult to classify, associated with pain or blood in the urine, accompanied by recurrent urinary infections or pelvic pressure, or significantly affecting daily life. Assessment may include a bladder diary, urine testing, pelvic-floor examination or specialist investigations depending on the clinical picture.
It is also important to distinguish stress incontinence from urgency-predominant symptoms, overflow problems, infection, pelvic-organ prolapse and other causes because each may require a different management approach.
When should I see a doctor?
Seek medical assessment for bladder-control problems that are persistent, worsening or affecting daily life. Prompt review is particularly important if urinary leakage occurs with:
- blood in the urine;
- pain or burning when passing urine that does not settle;
- recurrent urinary infections;
- difficulty emptying the bladder;
- new pelvic pain, pressure or a vaginal bulge;
- new neurological symptoms; or
- any significant change in bladder function that concerns you.
These symptoms can have causes other than stress urinary incontinence and may require further investigation.
Frequently asked questions
Is PRP an established treatment for stress urinary incontinence?
No. PRP is being studied for SUI, but current research is limited and mixed. It should not be presented as an established first-line treatment.
Do studies show that PRP works for every woman with SUI?
No. Some studies report improvement, while others have not shown a significant advantage over placebo for their primary outcome. Individual results cannot be predicted from these small studies.
How many PRP treatments are needed for SUI?
There is no established evidence-based protocol. Studies have used different schedules, which is one reason the optimal approach remains uncertain.
Is pelvic-floor physiotherapy still important?
Yes. Pelvic-floor muscle training is an established conservative management option for many women with SUI and can be tailored after assessment.
What if pelvic-floor treatment has not been enough?
Further assessment can confirm the type and severity of incontinence and help determine whether additional conservative measures, continence devices, specialist procedures or surgery should be discussed.
Is PRP proven to be safe long term for SUI?
Current studies are too small and follow-up is too limited to define uncommon or long-term risks with confidence. Short-term trial reporting does not answer every safety question.
Related Géniale Intimate information
Medical references and further reading
- Healthdirect Australia — Urinary incontinence
- Continence Health Australia — Stress incontinence
- Grigoriadis et al. — Randomized trial of PRP for stress urinary incontinence
- Ashton et al. — Randomized placebo-controlled single-injection trial
- Saraluck et al. — PRP plus pelvic-floor muscle training randomized trial
- Utama et al. — 2026 systematic review and meta-analysis
Clinical and regulatory review: Required before public publication. This draft is written as general education and does not recommend PRP as an established treatment or confirm treatment availability. A genuine clinician reviewer and review date should be added only after review.
Understand urinary incontinence first
Different types of urinary leakage have different causes and management pathways. Read the broader Géniale Intimate guide to assessment and treatment options.
Read About Urinary IncontinenceThis page provides general information and does not replace individual medical advice. Assessment and management depend on individual clinical circumstances.
